Nucleai, Mayo Clinic partner on digital pathology

By The Science Advisory Board staff writers

June 8, 2023 -- Nucleai and Mayo Clinic BioPharma Diagnostics on Monday announced a strategic collaboration involving digital pathology solutions, technologies, and services to support drug development and clinical practice.

The collaboration combines Nucleai's artificial intelligence (AI)-enabled spatial biology technology with Mayo's longitudinally annotated, multimodal data sets, lab services, and clinical diagnostic footprint.

Nucleai and Mayo Clinic will focus on several distinct offerings to support drug development, including biomarker discovery and validation, end-to-end spatial biology testing, and algorithm deployment for clinical trials and diagnostic use.

"By combining Mayo Clinic's extensive multimodal datasets, laboratories, and clinical expertise with Nucleai's advanced AI platform, we can bring scale and impact to the entire precision medicine landscape," Avi Veidman, CEO of Nucleai, said in a statement.

Copyright © 2023

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.